---
title: "GRAIL | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 40.79 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285258249.md"
datetime: "2026-05-05T20:12:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285258249.md)
  - [en](https://longbridge.com/en/news/285258249.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285258249.md)
---

# GRAIL | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 40.79 M

Revenue: As of FY2026 Q1, the actual value is USD 40.79 M, beating the estimate of USD 39.15 M.

EPS: As of FY2026 Q1, the actual value is USD -2.29, beating the estimate of USD -2.7629.

EBIT: As of FY2026 Q1, the actual value is USD -143.75 M.

#### Revenue

Total revenue for GRAIL, Inc. increased by 28% year-over-year to $40.8 million in the first quarter of 2026 . This includes screening revenue of $39,832 thousand and development services revenue of $953 thousand . Galleri revenue specifically grew by 37% year-over-year to $39.8 million .

#### Operational Metrics

GRAIL, Inc. reported a net loss of - $93.2 million for the first quarter of 2026, marking an improvement of $13.0 million or 12% compared to the prior year . The gross loss was - $14.3 million, an improvement of $5.6 million or 28% year-over-year . Non-GAAP adjusted gross profit was $19.7 million, an increase of $5.4 million or 38% . Non-GAAP adjusted EBITDA was - $79.9 million, an improvement of $18.8 million or 19% . The loss from operations improved to - $135,765 thousand in Q1 2026 from - $153,607 thousand in Q1 2025 .

#### Operating Costs

Total costs and operating expenses were $176,550 thousand for the three months ended March 31, 2026, compared to $185,444 thousand for the same period in 2025 . Research and development expenses decreased to $48,021 thousand in Q1 2026 from $53,625 thousand in Q1 2025 . Sales and marketing expenses were $30,668 thousand in Q1 2026, down from $34,979 thousand in Q1 2025 . General and administrative expenses were $42,769 thousand in Q1 2026, compared to $45,074 thousand in Q1 2025 .

#### Cash Position

As of March 31, 2026, cash, cash equivalents, and short-term marketable securities totaled $823.1 million . Specifically, cash and cash equivalents were $69,344 thousand and short-term marketable securities were $753,761 thousand .

#### Unique Metrics

Galleri test volume increased by 50% year-over-year to more than 56,000 tests in the first quarter of 2026 .

#### Outlook / Guidance

GRAIL, Inc. anticipates broad availability of the Galleri test within the Epic electronic health record (EHR) platform by the end of 2026, aiming to expand access for physicians and patients nationwide . The company’s Premarket Approval (PMA) application for Galleri was accepted by the U.S. Food and Drug Administration (FDA) for review in January . Detailed results from the 35,000 PATHFINDER 2 study and the 140,000 NHS-Galleri trial are scheduled to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in late May .

### Related Stocks

- [GRAL.US](https://longbridge.com/en/quote/GRAL.US.md)

## Related News & Research

- [GRAIL Says Galleri Demand Is Rising as NHS Talks, FDA Review Move Ahead](https://longbridge.com/en/news/286677381.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [The Seed 40: The best women early-stage investors of 2026](https://longbridge.com/en/news/286743171.md)
- [OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 | OSTX Stock News](https://longbridge.com/en/news/286607728.md)